+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
NEULANDLAB

Neuland Laboratories Share Price

 
60.30% Gain from 52W Low

 

Neuland Laboratories live price: ₹18,434.00. It opened at ₹18,751 vs previous close ₹18,751; intraday high/low: ₹18,951/₹18,055. The 50 & 200 DMA stand at ₹17,541.00/₹15,493.60.

Neuland Laboratories Performance

  • Today's Low
  • ₹18,055
  • Today's High
  • ₹18,951
  • 52 Week Low
  • ₹11,500
  • 52 Week High
  • ₹20,089
  • Open Price₹18,751
  • Previous Close₹18,751
  • Volume42,163
  • 50 DMA₹17,541.00
  • 100 DMA₹16,476.70
  • 200 DMA₹15,493.60

Neuland Laboratories Chart

Investment Returns

  • Over 1 Month + 8.33%
  • Over 3 Month + 20.52%
  • Over 6 Month + 30.86%
  • Over 1 Year + 27.1%

Smart Investing Starts Here Start SIP with Neuland Laboratories for Steady Growth!

Invest Now

Neuland Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 65
  • PEG Ratio
  • 1.6
  • Market Cap Cr
  • 23,651
  • P/B Ratio
  • 12.6
  • Average True Range
  • 617
  • EPS
  • 283.7
  • Dividend Yield
  • 0
  • MACD Signal
  • 457.3
  • RSI
  • 52.28
  • MFI
  • 69.41

Latest Stock News Updates

Neuland Laboratories Ltd - 524558 - Announcement under Regulation 30 (LODR)-Credit Rating

Announcement under Regulation 30 (LODR) - Credit Rating

Neuland Laboratories Ltd - 524558 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication regarding dispatch of notice of 42nd Annual General Meeting and Integrated Annual Report for FY 2025-26

Neuland Laboratories Ltd - 524558 - Letter To The Shareholders Of The Company In Relation To The Notice Of 42Nd Annual General Meeting And Integrated Annual Report Of The Company For FY 2025-26

Letter to the Shareholder of the Company in relation to the Notice of 42nd Annual General Meeting and Integrated Annual Report of the Company for FY 2025-26

Neuland Laboratories Financials

Neuland Laboratories Technicals

EMA & SMA

Current Price
₹18,434.00
-317 (-1.69%)
pointer
  • Bearish Moving Average 7
  • Bullish Moving Average 9
  • 20 Day
  • ₹18,546.20
  • 50 Day
  • ₹17,541.00
  • 100 Day
  • ₹16,476.70
  • 200 Day
  • ₹15,493.60

Resistance and Support

18480 Pivot Speed
  • R3 19,801.00
  • R2 19,376.00
  • R1 18,905.00
  • S1 18,009.00
  • S2 17,584.00
  • S3 17,113.00

Neuland Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-12 Audited Results & Final Dividend
2026-02-09 Quarterly Results
2025-11-07 Quarterly Results
2025-07-31 Quarterly Results
2025-05-15 Audited Results & Final Dividend
Date Purpose Remarks
2026-07-24 FINAL Rs.34.00 per share(340%)Final Dividend
2025-07-18 FINAL Rs.12.00 per share(120%)Final Dividend
2022-07-15 FINAL Rs.5.00 per share(50%)Final Dividend
View Neuland Laboratories Dividend History Arrow

Neuland Laboratories Shareholding Pattern

32.63%
31.08%
20.46%
11.35%
4.49%

About Neuland Laboratories

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. View More
  • NSE Symbol
  • NEULANDLAB
  • BSE Symbol
  • 524558
  • Executive Director,Managing Director,Chief Executive Officer
  • D Saharsh Rao
  • ISIN
  • INE794A01010

Similar Stocks to Neuland Laboratories

Neuland Laboratories FAQs

Neuland Laboratories share price is ₹18,434 As on 18 July, 2026 | 07:56

The Market Cap of Neuland Laboratories is ₹23650.6 Cr As on 18 July, 2026 | 07:56

The P/E ratio of Neuland Laboratories is 65 As on 18 July, 2026 | 07:56

The PB ratio of Neuland Laboratories is 12.6 As on 18 July, 2026 | 07:56

The 52 week High & Low of Neuland Laboratories is ₹20089/₹11500 respectively As on 18 July, 2026 | 07:56

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23